GH Research PLC - Ordinary Shares (NQ:GHRS)

22.94 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GH Research PLC - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Largest Psychedelic Compound -Based Clinical-Stage Drug Stocks Up 6% Last Week ↗

August 24, 2024

Opportunities to invest in psychedelic stocks are emerging for those willing to get in early, and the 4 largest psychedelic compound-based portfolio drug discovery companies are up 5.9% in the past...

Via Talk Markets

Psychedelic Compound-Based Drug Stocks Portfolio: Up 17.5% In July; Down 19% MTD ↗

August 15, 2024

This article highlights the 4 largest market cap clinical-stage psychedelic compound-based drug discovery companies with their stock performances MTD, in July, their areas of focus, and their latest...

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Jumped 10% Last Week; UP 13% MTD ↗

July 14, 2024

The 10 clinical-stage AI-focused and psychedelic compound-based drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio are UP 12.8% MTD after having gone DOWN 13.2%, on average,...

Via Talk Markets

3 Psychedelic Stocks to Ride to the Moon and Beyond ↗

July 06, 2024

Psychedelic stocks are a hot, trending area of investment as the FDA continues to weigh regulatory considerations that will open the market.

Via InvestorPlace

Psychedelic Picks: 3 Trippy Stocks Aiming for Out-of-This-World Returns ↗

July 03, 2024

Psychedelics could be a game-changer in treating mental health issues, creating substantial opportunities for top psychedelic stocks.

Via InvestorPlace

GH Research: Q4 Earnings Insights ↗

February 29, 2024

Via Benzinga

Largest Clinical-Stage BioTech Drug Stocks Declined 6% ↗

June 22, 2024

Of the 10 clinical-stage AI-focused and psychedelic compound-based small cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, only 1 advanced this week. On average they...

Via Talk Markets

Largest Psychedelic Compound Based Drug Stocks Fell 13% Last Week - Here's Why ↗

June 09, 2024

Stocks for companies developing psychedelic treatments fell last Wednesday after advisers to the Food and Drug Administration voted against a mental-health therapy using the drug MDMA.

Via Talk Markets

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

June 05, 2024

Via Benzinga

Largest Clinical-Stage BioTech Drug Stocks Declined Slightly Last Week ↗

May 27, 2024

This article highlights the performances last week and MTD of the 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies along with their areas of focus in our...

Via Talk Markets

Largest Clinical-Stage BioTech Drug Stocks Declined 3% Last Week ↗

May 13, 2024

Via Talk Markets

Clinical-Stage BioTech Drug Stocks Portfolio Jumped 7% In First Week Of May ↗

May 05, 2024

We look at the performance of 10 clinical-stage AI-powered and psychedelic compound-based small cap drug discovery companies during the first week of May and YTD.

Via Talk Markets

GHRS Stock Earnings: GH Research Beats EPS for Q1 2024 ↗

May 03, 2024

GHRS stock results show that GH Research beat analyst estimates for earnings per share the first quarter of 2024.

Via InvestorPlace

GH Research Reports First Quarter 2024 Financial Results and Provides Business Updates

May 03, 2024

From GH Research PLC

Via GlobeNewswire

Clinical-Stage BioTech Drug Stocks Portfolio Went Down 9% Last Week ↗

April 23, 2024

A look at the 10 clinical-stage AI-powered and psychedelic compound-based small-cap drug discovery companies in our Clinical-Stage BioTech Drug Stocks Portfolio, their stock performances last week and...

Via Talk Markets

Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More ↗

April 17, 2024

Via Benzinga

Largest Psychedelic Drug Stocks Up Another 10% Last Week; Now Up 54% YTD ↗

April 12, 2024

The 5 constituents in the Psychedelic Compound-Based Drug Stocks Index were up 10.0%, on average, last week and are now up 53.9% YTD.

Via Talk Markets

March Recap: Largest Psychedelic Drug Stocks Up Another 5% ↗

March 30, 2024

The 5 constituents in the munKNEE Psychedelic Compound-Based Drug Stocks Index were UP 5.4%, on average, in March and are now UP 39.9% YTD.

Via Talk Markets

Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence ↗

March 29, 2024

Via Benzinga

Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More ↗

March 20, 2024

Via Benzinga

Topics Economy

Psychedelic Compound-Based Drug Stock, Mind Medicine, Up 56% Last Week ↗

March 11, 2024

The FDA has granted breakthrough designation to Mind Medicine's program for the treatment of generalized anxiety disorder.

Via Talk Markets

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

Largest Psychedelic Compound-Based Drug Stocks Up 15% In February; Now Up 33% YTD ↗

March 01, 2024

The Psychedelic Compound-Based Drug Stocks Index was up 15.0% in February led by Incannex Healthcare which was up 55.1%.

Via Talk Markets

GH Research: This European Biotech Company Reports Full Year 2023 Financial Results And Business Updates ↗

February 29, 2024

Via Benzinga

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

February 29, 2024

From GH Research PLC

Via GlobeNewswire

Psychedelic Stocks Index Popped 8% Last Week, Led By Incannex ↗

February 18, 2024

IXHL 's increase was based on the successful completion of an Investigational New Drug meeting with the U.S. Food and Drug Administration regarding the development of CannQuit-N for tobacco smoking...

Via Talk Markets

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

5 Largest Psychedelic Compound-Based Drug Stocks Up 17% Last Week ↗

January 30, 2024

The 5 constituents in the Psychedelic Drug Stocks Index jumped 16.7%, on average, last week and are now up 11.7% MTD.

Via Talk Markets

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More ↗

January 26, 2024

Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available.

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.